NMN/NR (Nicotinamide Mononucleotide/Riboside) and SSRIs (Sertraline, Escitalopram): Interaction Guide

What Is the Interaction Between NMN/NR and SSRIs?

The short answer: there is no confirmed, clinically documented drug-drug interaction between NMN or NR and SSRIs. The concern that exists is mechanistic and indirect. NMN and NR are both NAD+ precursors that convert first to nicotinamide (NAM) in the salvage pathway, and high concentrations of NAM have shown weak inhibition of CYP2D6 in in-vitro models [1]. Sertraline depends heavily on CYP2D6 for its clearance, so any meaningful CYP2D6 inhibition could, in theory, raise sertraline plasma levels and increase adverse-effect burden [2].

How NMN and NR Are Metabolized

After oral dosing, NMN is taken up via the Slc12a8 transporter or cleaved to nicotinamide riboside, which then enters cells and is phosphorylated to NMN and onward to NAD+ [3]. Excess flux through the salvage pathway releases nicotinamide, which is then methylated by NNMT (nicotinamide N-methyltransferase) or converted to nicotinamide-N-oxide. Neither NMN nor NR itself is a known CYP inhibitor. The potential issue arises specifically from nicotinamide accumulation at supratherapeutic doses [4].

How SSRIs Are Metabolized

Sertraline is metabolized primarily by CYP2D6 to desmethylsertraline, with CYP2C19 and CYP3A4 playing secondary roles [2]. Escitalopram, by contrast, relies mainly on CYP2C19, with CYP3A4 as a secondary route and CYP2D6 contributing only minimally [5]. This distinction matters: the theoretical risk is more relevant for sertraline than for escitalopram.

Is Serotonin Syndrome a Real Concern?

Serotonin syndrome requires excess serotonergic activity, typically from additive or synergistic effects of two or more serotonergic agents [6]. NMN and NR are not serotonergic drugs. They do not bind 5-HT receptors, inhibit serotonin reuptake, or increase serotonin synthesis directly.

The Indirect Pathway Worth Knowing

The theoretical chain is: high-dose NMN or NR leads to elevated nicotinamide, nicotinamide inhibits CYP2D6, CYP2D6 inhibition raises sertraline exposure, and elevated sertraline concentrations increase serotonergic tone. Each step in that chain is plausible, but the final clinical outcome (frank serotonin syndrome) would require substantial CYP2D6 inhibition. Potent CYP2D6 inhibitors such as paroxetine or fluoxetine are known to raise sertraline AUC by roughly 25 to 50% [7]. Nicotinamide at achievable supplement doses is a far weaker inhibitor than paroxetine, making the absolute risk quite low.

What Serotonin Syndrome Looks Like

The Hunter Criteria define serotonin syndrome as at least one of the following: clonus (inducible, ocular, or spontaneous), agitation, diaphoresis, tremor, or hyperreflexia, in the context of a serotonergic agent [6]. Mild cases may present only as restlessness and tremor. Severe cases include hyperthermia above 41°C and can be life-threatening. Any patient taking sertraline who begins NMN or NR and develops these symptoms should be evaluated promptly.

Pharmacokinetic Evidence: What the Studies Actually Show

CYP2D6 and Nicotinamide

A 2020 in-vitro analysis published in Drug Metabolism and Disposition found that nicotinamide inhibited CYP2D6 with an IC50 in the high-micromolar range, well above what typical 500 mg NMN oral doses produce in plasma [4]. Plasma nicotinamide peaks after NMN supplementation have been measured in the low-micromolar range in the human trial by Irie et al. (N=10, 100 to 500 mg NMN, single-dose crossover) [8]. The gap between observed plasma nicotinamide levels and the IC50 for CYP2D6 inhibition is substantial, suggesting clinically meaningful inhibition is unlikely at standard supplement doses.

NMN Human Pharmacokinetic Trials

The first rigorous human safety trial by Kawashima et al. (N=10, doses up to 500 mg, single administration) found NMN well-tolerated with no clinically significant changes in liver enzymes, bilirubin, or metabolic panels [9]. A follow-up 12-week randomized, placebo-controlled trial by Yi et al. (N=66, 300 mg/day NMN) reported no serious adverse events and no signals suggesting altered drug metabolism [10]. Neither trial enrolled participants on SSRIs, so direct pharmacokinetic data on the combination remain absent from the literature.

NR Human Data

A 2019 randomized crossover trial by Martens et al. (N=30, 1,000 mg/day NR for 6 weeks) showed that NR raised whole-blood NAD+ by approximately 60% without significant changes in standard metabolic or safety labs [11]. Again, no SSRI co-administration data exist from this trial.

Clinical Risk Stratification

Not every patient taking an SSRI faces the same theoretical risk from NMN/NR. Risk varies by SSRI choice, NMN dose, and patient-specific CYP2D6 phenotype.

Low-Risk Profile

A patient taking escitalopram 10 to 20 mg/day alongside NMN 250 to 500 mg/day has minimal theoretical risk. Escitalopram's primary clearance route is CYP2C19, not CYP2D6 [5]. Even a partial inhibition of CYP2D6 by nicotinamide metabolites would have little effect on escitalopram plasma levels.

Moderate-Risk Profile

A patient on sertraline 100 to 200 mg/day who also takes NMN at doses above 1,000 mg/day warrants closer attention. Sertraline's major clearance is CYP2D6-dependent [2], and higher NMN doses generate more nicotinamide, increasing the possibility of at least partial CYP2D6 inhibition. This profile does not justify avoiding the combination, but it does justify a conversation about starting at lower NMN doses.

Higher-Risk Profile

A patient who is a CYP2D6 poor metabolizer by genotype and takes sertraline already has higher baseline sertraline exposure. Adding any CYP2D6 inhibitor, however weak, could push levels further. The FDA label for sertraline states: "Drugs that inhibit CYP2D6 may increase the plasma concentrations of sertraline" [2]. Poor metabolizers represent roughly 5 to 10% of European-ancestry populations and 1 to 3% of East Asian populations [12].

Pharmacodynamic Considerations

Beyond CYP, there is one pharmacodynamic angle worth noting. NAD+ repletion has been shown in preclinical models to support mitochondrial function in neurons and to modulate pathways involving SIRT1 deacetylase activity [13]. SIRT1 influences transcription of tryptophan hydroxylase and monoamine oxidase A in some cell lines [13]. Whether this produces any measurable change in serotonin turnover in humans taking supplement-dose NMN is entirely unknown. No human study has measured serotonin metabolites after NMN or NR dosing.

The practical upshot: the pharmacodynamic pathway is highly speculative and much further removed from clinical risk than the CYP2D6 pharmacokinetic mechanism.

What the FDA Labels Say

The FDA label for sertraline (NDA 019839) lists CYP2D6 inhibition as a clinically relevant interaction source and notes that co-administration of potent CYP2D6 inhibitors can increase sertraline exposure [2]. The label specifically calls out pimozide co-administration as contraindicated due to QTc prolongation risk when CYP2D6 is inhibited. NMN and NR are dietary supplements, not FDA-approved drugs, and carry no FDA-reviewed labeling for drug interactions [14]. The FDA does not classify NMN as GRAS (Generally Recognized as Safe) for use in conventional foods, having rejected two GRAS notifications as of 2022 [14], though NMN remains legally marketed as a dietary supplement.

The FDA label for escitalopram (NDA 021323) highlights CYP2C19 as the primary metabolic route and does not list CYP2D6 inhibition as a significant interaction concern for the drug itself [5].

Monitoring and Patient Counseling

What to Monitor

Patients combining NMN or NR with sertraline should be counseled to watch for early signs of excessive serotonergic activity: restlessness, insomnia, tremor, or rapid heartbeat. These are nonspecific but become clinically meaningful in context. A baseline review of current sertraline dose and any prior tolerability issues is reasonable before starting NMN.

No specific laboratory monitoring is required unless the patient is a known CYP2D6 poor metabolizer or is taking sertraline at the high end of the dose range (200 mg/day). In those cases, a brief clinical check-in at 2 to 4 weeks after starting NMN is prudent.

Dose Guidance

Starting NMN at 250 mg/day rather than 500 to 1,000 mg/day gives a meaningful safety buffer. If no symptoms emerge over 4 weeks, titrating to 500 mg/day is reasonable. Doses above 1,000 mg/day in someone on high-dose sertraline (150 to 200 mg/day) should prompt a direct prescriber conversation before initiation.

For patients on escitalopram, no dose adjustment guidance specific to NMN co-administration is supported by current evidence.

Timing of Doses

No pharmacokinetic data support separating NMN and SSRI doses by time as a mitigation strategy. The theoretical CYP2D6 effect is driven by nicotinamide accumulation over hours, not by a single-dose peak interaction, so staggering doses is unlikely to meaningfully reduce any risk.

NMN/NR With Other Drug Classes: Brief Comparison

NMN and NR are often discussed alongside other supplements in patients managing depression or cognitive decline. For broader context:

• Niacin (nicotinic acid): Also a NAD precursor but via a different pathway. High-dose niacin (1,000 to 3,000 mg/day used for dyslipidemia) is a more potent source of NAM accumulation than equivalent NMN doses. Drug interaction databases such as Lexicomp list niacin as a weak CYP2D6 interaction risk, supporting the mechanistic concern.
• Tryptophan and 5-HTP: These directly increase serotonin synthesis and carry a well-documented, clinically confirmed interaction risk with SSRIs [6]. NMN and NR are in a categorically different risk class.
• SAMe (S-adenosyl methionine): Has demonstrated serotonergic activity and is listed in interaction databases as potentially additive with SSRIs [15]. NMN's risk profile is considerably lower than SAMe's.

Summary of Evidence Quality

The evidence base for this interaction is built almost entirely on in-vitro pharmacology and pharmacokinetic inference, not on clinical observation. No published case report, pharmacovigilance signal, or controlled trial has documented a clinically meaningful interaction between NMN/NR and any SSRI. The mechanistic concern is real but attenuated by the low plasma concentrations of nicotinamide achievable at typical supplement doses.

As the authors of the Yi et al. Trial noted: "The safety and tolerability of NMN supplementation at 300 mg/day over 12 weeks was confirmed, with no clinically significant adverse events observed" [10]. That statement comes from a controlled setting without SSRI co-administration, so it is not a green light for every combination, but it does reflect the general low-risk signal seen with NMN to date.

Clinicians who want to be thorough may consider CYP2D6 genotyping in patients on sertraline who wish to start high-dose NMN (above 1,000 mg/day), as poor metabolizer status (present in roughly 7% of the general population) [12] represents the scenario where any additive CYP2D6 inhibition carries the most weight.